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ABSTRACT
Chronic Myeloid Leukemia (CML) is a stem cell disease sustained by a rare 
population of quiescent cells which are to some extent resistant to tyrosine kinase 
inhibitors (TKIs). BCR-ABL oncogene activates multiple cross-talking signal transduction 
pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt and STAT5, contributing to 
abnormal proliferation of clonal cells. From this perspective, the aim of this study was 
to analyze the expression and activation profile of STP involved in the mechanisms of 
cell proliferation/quiescence and survival of the progenitor CD34+ cells from chronic 
phase (CP) CML. 
Our results showed that CP-CML CD34+ progenitors were characterized by 
significant lower phosphorylation of proteins involved in the regulation of growth and 
cell survival, such as tyrosine kinases of the Src family and members of STAT family, and 
by a significant higher phosphorylation of p53 (Ser15), compared to normal CD34+ cells 
from healthy donors. Consistent with these results, cell cycle analysis demonstrated 
that CP-CML CD34+ cells were characterized by higher percentage of cells in G0-phase 
compared to normal CD34+ cells. Analysis of expression profile on proteins involved 
in the apoptotic machinery revealed that, in addition, CD34+ cells from CP-CML were 
characterized by a significant lower expression of catalase and higher expression of 
HSP27 and FADD. In sum, we report that CD34+ cells from CP-CML are characterized 
by a proteomic and phospho-proteomic profile that promotes quiescence through the 
inhibition of proliferation and the promotion of survival. This differential signaling 
activation network may be addressed by novel targeted therapies aimed at eradicating 
CML stem cells. 
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INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal disorder 
originated from hematopoietic stem cells, pathogenically 
associated with reciprocal chromosomal translocation 
t(9;22), which gives rise to the fusion gene BCR-ABL, 
encoding for a protein of p210 kDa with a constitutively 
activated tyrosine kinase (TK) activity [1, 2]. Nowadays, 
the standard of care for patients with CML is represented by 
TK inhibitors (TKI activity) which inhibit the constitutive 
activation and subsequent proliferative functions of the 
onco-protein [3–8]. However, some patients become 
refractory to TKIs during treatment, suggesting the presence 
of resistance mechanisms. [9, 10]. While BCR-ABL 
mutations or amplification are generally recognized as the 
main causes of BCR-ABL-dependent mechanisms of TKI 
resistance, other studies have reported that the presence of 
quiescent Philadelphia positive (Ph+) stem cells could be an 
additional way to escape the TKIs activity [11–13]. 
Multiple mechanisms cooperate in promoting kinetic 
quiescence and prolonged survival of leukemic progenitor 
cells. However, many pathways involved in controlling 
these processes are also active in normal stem cells 
[14, 15]. Moreover, the activation status of specific signal 
transduction pathways (STP), such as PI3K/AKT/mTOR, 
Ras/Raf/MEK/ERK1/2, Wnt and STAT pathways [15, 16], 
as well as their interactions (cross-talking), play a crucial role 
both in normal and leukemic progenitor cell fate [17–20]. 
Revealing differentially activated components of these 
survival pathways could lead to a more effective eradication 
of the progenitor clonal cells, sparing normal counterparts.
While several studies have investigated at the 
genetic level the CML leukemia stem cells (LSCs) 
[15, 21–23], the post-translational modifications of the 
STP involved in the proliferation and survival machinery 
have not yet been explored.
The aim of this study was therefore to analyze at 
the protein level the expression profile and activation 
of numerous STP involved in the mechanisms of cell 
proliferation/quiescence and survival of CD34+ cells, 
obtained from samples of CML patients diagnosed in 
chronic phase (CP). Here, to the best of our knowledge, 
we report for the first time the proteomic and the phospho-
proteomic profile of CD34+ cells obtained from CP-CML 
patients, compared to CD34+ progenitors from healthy 
donors, showing that the former are characterized by a 
specific proteomic and phospho-proteomic profile that 
promotes quiescence and survival.
RESULTS 
Phospho-kinase proteomic profile of CD34+ cells 
from CP-CML patients
Phospho-Kinase Array Kit was used to detect the 
activation status of 45 phosphorylation sites belonging 
to several STP in CP-CML CD34+ cells compared to 
normal CD34+ cells. Phospho-proteomic array analysis 
identified that several (a) non-receptor tyrosine kinases 
members of  Src family, (b) components of different STP 
(p38, p-ERK1/2, CREB, MSK1/2, mTOR, GSK3a/b and 
β-catenin), and (c) key transcription factors including STAT 
family members were down-phosphorylated as compared to 
normal CD34+ cells (Figure 1). In particular, a statistically 
significant lower phosphorylation was found in four 
tyrosine kinases of the Src family (Lyn, Fyn, Yes: p = 0.02; 
Lck: p = 0.03), in three members of the STAT family 
(STAT2: p = 0.02; STAT5a and STAT5b: p = 0.045) and in 
FAK (p = 0.04). Moreover, an additional tyrosine kinase of 
the Src family (Fgr), two additional members of the STAT 
family (STAT3 and STAT6) and β-catenin resulted hypo-
phosphorylated in CP-CML, although they did not reach 
statistical significance (between p = 0.06 and p = 0.1).
On the contrary, other signaling molecules as 
well as p53, p27, paxillin and HSP27 resulted hyper-
phosphorylated in CP-CML CD34+ cells as compared 
to the normal CD34+ cells, but only p53 (Ser15) reached 
statistical significance (p = 0.047) 
Apoptotic proteomic profile of CD34+ cells from 
CP-CML patients
Apoptosis Array Kit was used to analyze the 
expression of 32 apoptosis/cell cycle related proteins in 
CP-CML CD34+ cells compared to normal CD34+ cells. 
Results revealed that CD34+ cells from CP-CML, as 
compared to normal CD34+ cells, are characterized by: 1) 
lower expression of catalase (p = 0.012), an enzyme that 
protects cells from the toxic effects of hydrogen peroxide 
and promotes growth of normal and neoplastic cells 
including myeloid leukemia cells; 2) higher expression of 
FADD (p = 0.038), a death receptor involved in extrinsic 
apoptosis and necroptosis, and of HSP70 (p < 0.001), 
crucial for cells survival after toxic stimuli (Figure 2).
Cell-cycle analysis and cell-cycle regulators’ 
protein expression
We also performed the cell cycle analysis of the 
CD34+ cells from the aforementioned sources by the AO 
ﬂow cytometric technique. The mean results are shown 
in Figure 3, demonstrating a lower percentage of cells 
in S-phase associated with a parallel increase of cells in 
G0-phase in CD34+ cells from CP-CML with respect to 
normal CD34+ cells indicating a larger pool of quiescent 
cells in CP-CML.  
DISCUSSION 
CML is a stem cell disease sustained by a rare 
population of kinetic quiescent cells. In the indolent CP 
of the disease those dormant cells provide a reservoir 
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for the Philadelphia chromosome. During the natural 
history of CML progenitors characterized by accumulated 
mutations due to increased genetic instability drive disease 
progression. As reviewed by Savona & Talpaz [15], in 
advanced phases, determinants of cell proliferation are 
indeed no longer addicted to BCR-ABL. Other aberrant 
signals induced by additional altered genes begin to 
autonomously control cell survival and proliferation, such 
as Src family kinase activation [15]. These observations 
could help explain why TKI therapy controls but fails to 
eliminate the disease. 
Thus, one of the main goals for the eradication of 
leukemia should be to determine and to hit the sanctuary 
of quiescent CP-stem cells. Recent studies have reported 
that signaling pathways involved in the regulation of 
hematopoietic stem cells self-renewal and development 
are also active in cancer, thus representing the main open 
question on the differential expression of quiescent CP-CML 
progenitors from their normal counterpart [17, 24, 25].
Moreover, it was reported that the BCR-ABL 
oncogene and the resulting fusion protein activate multiple 
cross-talking STP, such as RAS/MEK/ERK, PI3K/Akt, 
Wnt, STAT5 and Src family kinases, potentially contributing 
to abnormal proliferation of clonal cells [17, 22, 25–27]. 
Based on this rationale, the aim of this study was 
to analyze, at the protein level, the expression profile and 
activation of numerous STP involved in the mechanisms of 
cell proliferation and survival of normal and CML CD34+, 
in order to identify differential molecular characteristics 
of CML progenitors, potentially druggable for leukemia 
eradication.
Previous studies have profiled the transcriptome of 
CML progenitors by gene array technology [21, 28–30]. 
Bruns and colleagues [21] have evaluated the transcriptional 
characteristics of CP-CML progenitors and of normal 
myeloid progenitor cells. They demonstrated that CP-CML 
progenitors have a transcriptionally more mature phenotype 
than its normal counterpart, showing downregulation of 
Figure 1: (A) Human phospho-kinase array kit was used to detect the relative levels of kinase phosphorylation in cell lysates from CP-CML 
CD34+ cells and from normal CD34+ cells. Bar diagram shows quantitation of the array data expressed as reported in Mat&Met section. 
(*p < 0.05 by two-tailed Student’s t test for the comparison between normal and CP-CML CD34+ cells). (B) Membrane hybridization and 
(C) densitometric quantitation are depicted for STAT2(Y689) as representative example. 
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genes encoding adhesion molecules as well as decreased 
expression of transcription factors, stem-cell regulators and 
inhibitors of cell proliferation [21].
Information derived from genomic approaches 
have recently been also complemented and extended to 
the evaluation of proteomic profiles, which are able to 
highlight the protein post-translational modifications that 
play a major role in regulating protein activities, crosstalk 
and subcellular localization. In a pioneering study designed 
to identify cellular pathways affected by imatinib treatment, 
Xiong and colleagues [31] employed LC-MS/MS, through 
a SILAC approach, to assess and quantify the imatinib-
induced protein expression variation in the BCR-ABL-
positive human K562 cell line. Their results showed that 
imatinib induced a signiﬁcantly altered level of expression 
in 73 out of 1344 quantiﬁed proteins [31]. Subsequently, 
the Kornblau group evaluated by Reverse Phase Protein 
Array (RPPA), the protein expression patterns of samples 
obtained from CML patients in order to differentially 
identify STP that predicted disease progression [32]. 
Although they used unsorted CML samples, Kornblau and 
colleagues reported that several proteins (HSP90, Rb, AIF, 
PP2A, Bcl-2, Xiap, Smad1, SSBP2a, PARP, Gab2, and 
TRIM24) were overexpressed in advanced-phase CML 
patients, as compared with those in CP [32]. Analysis of 
altered proteins related to blast crisis (BC), performed by 
using two-dimensional (2D) gel electrophoresis technique, 
identiﬁed 13 up-regulated proteins in BC-CML patients as 
compared to CP-CML, most of which were involved in 
the proteosome and in the small G-protein pathway [33]. 
Other studies have focused on the proteomic profile of 
CML. Peng and colleagues have evaluated the leukemia cell 
line K562 and their adriamycin-resistant counterpart [34], 
while Alaiya et al. have focused on the detection of protein 
biomarkers present in plasma from CML patients [35], 
showing the importance of this approach, which allowed the 
identification of both mechanism of adriamycin resistance 
and of molecular response to therapy, respectively.
Nevertheless, little is known about the proteomic 
profile of CML CD34+ progenitors. Thus, to the best 
Figure 2: Cell lysates from CP-CML CD34+ cells and from normal CD34+ cells were analyzed for the expression of 
proteins which participate in apoptosis/cell survival modulation by using human apoptosis array kit. (A) Bar diagram 
shows quantitation of the array data expressed as reported in Mat&Met section. (*p < 0.05 by two-tailed Student’s t test for the comparison 
between normal and CP-CML CD34+ cells). (B) Membrane hybridization and (C) densitometric quantitation are depicted for HSP70, as 
representative example. 
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of our knowledge, we analyzed for the first time the 
proteomic and the phospho-proteomic profile of CD34+ 
cells obtained from CP-CML, as compared to their normal 
CD34+ counterpart. 
Phospho-proteomic array analysis between normal 
and CP-CML CD34+ cells revealed differences in the 
activation profile of several proteins. In particular, 
statistically significant differences were observed in 
members of the Src and of the STAT family (both involved 
in the regulation of growth and cell survival), in FAK, (a 
crucial regulator of cell migration) and in p53.  
Our finding about the lower phosphorylation of four 
kinases belonging to Src family (Lck, Lyn, Fyn, Yes) in the 
CP of the disease is intriguing, since previous observations 
reported increased expression and phosphorylation of 
members of Src family in patients with CML in BC, evoking 
its role as possible mechanisms of resistance to TKI, 
independent from BCR-ABL [15, 36–38]. Specifically, Ban 
and co-workers have reported that the expression of Fyn is 
significantly increased in CML patients in BC as compared 
to those in CP and that the overexpression of BCR-ABL 
was associated with up-regulation of transcription and 
translation of Fyn [36]. Similarly, it has been shown that 
the overexpression of Lyn characterizes a more advanced 
stage of the disease [37]. Moreover, it was reported that 
the interplay between Syk and Lyn has a role in mediating 
nilotinib resistance in K562 cell line and in CD34+ cells 
isolated from CML patient blood samples [38]. 
Data from our group has previously demonstrated 
that progenitor biology largely depends on their kinetic 
status [29, 39]. Thus, we posed the question whether the 
differences and the similarities observed in the proteomic 
profile of CD34+ cells belonging to CP-CML compared 
to normal would reflect in the cell cycle distribution. To 
test this hypothesis, we performed a cell cycle analysis 
of the CD34+ cells by the AO ﬂow cytometric technique 
Figure 3: CP-CML CD34+ cells and normal CD34+ cells were analyzed by ﬂow cytometry for cell cycle distribution 
as described in Mat&Met. The results are expressed as mean percentage ± SD of cells in each phase of cell cycle. 
Oncotarget21763www.oncotarget.com
demonstrating a larger pool of quiescent (dormant) cells in 
CD34+ cells from CP-CML with respect to normal ones. 
This result is in line with the lower activation of proteins 
belonging to STP mostly involved in cell proliferation 
(elements of Raf/MEK/ERK1/2 pathway, of Src or STATs 
family) of CD34+ cells from CP-CML patients.
Diaz-Blanco et al. [22], examining the genome-wide 
gene expression signature of highly enriched CD34+ cells 
from CP-CML patient, found that CP-CML CD34+ cells 
compared to normal CD34+ cells were characterized by a 
higher expression level of proliferation-associated genes 
(components of Raf/MEK/ERK1/2 and PI3K/AKT/mTOR 
pathway and some genes of the JNK and p38 MAPK 
pathways) [22]. In contrast, looking at a post-translational 
level, our results reveal a hypo-phosphorylation of the 
same proliferative pathways analyzed by gene profile in 
CP-CML CD34+ cells compared to normal CD34+. Our 
finding of an under-activation status of CP-CML CD34+ 
cells signaling is coherent with a low rate of cycling 
cells and with a reported resistance to cytotoxic cell 
cycle-related agents. The hypothetical model suggested 
by our results indicates that the quiescent CP-CML are 
characterized by a downregulation of the Src family, 
making them insensitive to TKIs. In the non-quiescent 
bulky population, the hyper-activation of the Src family 
members, as well as others STPs, provide the target for 
these agents. In this view, the TKIs resistance of CP-
CML CD34+ is mainly due to lack of target, rather than to 
intrinsic mechanisms such as mutations or amplifications 
(Figure 4). 
Moreover, we observed a significantly higher 
phosphorylation of p53 at Ser15 in CP-CML CD34+ 
cells compared to the normal CD34+ cells. Since it was 
demonstrated that phosphorylation of p53 on Ser15 by 
ATM, ATR, DNA-PK and by Chk2 upon DNA damage is 
crucial for inducing cell cycle arrest, our finding further 
supports the more pronounced resting status of CP-CML 
CD34+ cells. The role of p53 in CML has already been 
investigated by other groups. Carter and colleagues [40] 
have analyzed the expression of p53 and MDM2 in BC-
CML cells and in proliferating and quiescent CD34+ 
CML progenitor cells, demonstrating a heterogeneous 
expression in cells from BC-CML patient samples. In 
addition they demonstrated that activation of p53 via 
MDM2 inhibition triggers apoptosis in blast cells, as well 
as in proliferating and quiescent CD34+ cells obtained 
from patients with BC-CML [40]. More recently, using 
an unbiased system biology approach, Abraham et al. [41] 
demonstrated that p53 and c-Myc are the key proteins in 
regulating the intracellular network of CML. They found 
that CML cells are characterized by higher c-Myc and 
lower p53 levels compared to normal CD34+ obtained 
from leukapheresis products or cord blood [41]. Moreover, 
they demonstrated that the simultaneous activation of p53 
and inhibition of c-Myc decrease viability and induce 
apoptosis of CML LSCs without measurable effects on 
normal HSCs [41]. However, this elegant work does not 
include p53 post-translational modifications analysis. 
We investigated the p53 phosphorylation status at Ser15 
also in CD34+ from cord blood and from leukapheresis 
Figure 4: Schematic hypothetical model of CP-CML CD34+ cell biological characteristics as compared to normal 
progenitor and proliferating CML cells. The downregulation of signals may confer TKI insensitiveness on CP-CML CD34+ 
progenitors. In the nuclei, cell cycle distributions are summarized.
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product, observing a similar phosphorylation levels 
when compared to CD34+ cells obtained from CP-CML 
(data not shown), thus suggesting a possible role of the 
endosteal niche in controlling p53 phosphorylation. 
More recently, our group has investigated the 
miRNA expression profile of different subpopulations 
of CML LSCs which have been previously shown to be 
endowed with TKI intrinsic resistance [42]. This study 
detected in the progenitor population from CP-CML the 
up-regulation of miR-29a-3p and miR-15 660-5p and the 
down-regulation of miR-494-3p, leading to a reduced 
susceptibility to the TKI-induced apoptosis. These 
results demonstrated that aberrant miRNA expression in 
CML could contribute to the intrinsic TKI-resistance via 
proliferative and apoptotic aberrant RNA-regulation.
In conclusion, we report here that CD34+ progenitor 
cells obtained from CP-CML patients, compared to CD34+ 
from healthy donors, are characterized by a specific 
proteomic and phospho-proteomic profile that promotes 
quiescence and survival.
These observations strongly make the case for 
the necessity of a deeper understanding of molecular 
mechanisms that are deregulated in the progenitors of CP-
CML as compared to normal counterpart. The identification 
of differentially activated STP crucial for CML progenitor 
cell survival, resistance and progression should therefore 
lead to novel and more efficient drug design and therapies 
aiming to eradicate and not only to control the disease. In 
this respect, potentially new druggable targets have recently 
been identified: from survival factor belonging to different 
STP (such as Bcl6, GSK3β, BLK, CD25, CD70, SIRT1 
SMO, etc.) to p53, c-Myc, HDAC and to metabolic enzyme 
(i.e. ALOX5) [16]. Accordingly, several compounds able to 
modulate those targets have been evaluated in clinical trials. 
Further pre-clinical evaluation of the role of these new 
molecular targets, together with innovative technologies, 
will finally enable to develop innovative therapeutic 
approach based on quiescent CML progenitor eradication.
MATERIALS AND METHODS
CD34+ cells 
Ph+ CD34 + cells were purified by immunomagnetic 
separation from peripheral blood (PB) of seven patients 
with newly diagnosed CML patients in chronic phase, 
with a white blood cell count ranging between 41,900 
and 421,400. Six out of seven were with Intermediate 
Sokal Score, one with Low Score. The BCR-ABL fusion 
transcript was e14a2 (b3a2) in five patients, e13a2 (b2a2) 
in one patient; the coexistence of e14a2 and e13a2 was 
observed in the remaining case. Normal CD34+ cells, 
obtained from four normal bone marrow of healthy 
donors were purchased from StemCell Technologies 
(Vancouver Canada). CML samples were obtained from 
the Hematology Unit, Policlinico Sant’Orsola-Malpighi, 
Bologna, Italy. Written informed consent for in vitro 
studies was obtained from all patients in accordance with 
the Declaration of Helsinki. Cell number and viability 
were determined by triplicate trypan blue exclusion.
Protein expression profile 
Protein extracts were obtained by treating the 
cell samples for 30 minutes in ice with a lysing buffer 
containing 10 mM NaF, 1 mM Na3VO4, 150 mM 
NaCl, 1 mM MgCl2, 1 mM CaCl2, 0.1% NaN3, 
10 mM iodoacetamide, 3 mM PMSF, 1% Triton-X100 
supplemented with a cocktail of protease inhibitors (Roche 
Diagnostic Corp., Indianapolis, IN). Cell lysates were then 
centrifuged at 13000 rpm for 5 minutes and the protein 
material suspended in the supernatant was collected and 
quantified by spectrophotometer. The activation state of 
45 phosphorylation sites belonging to several intracellular 
STP kinases (Table 1) and the expression of 32 proteins 
most directly involved in the apoptotic machinery 
(Table 2) were quantified in 6/7 and in 5/7 samples, 
respectively, by using an antibody direct phase array 
(Human Phospho-Kinase Array Kit, ARY003, and Human 
Apoptosis Array Kit, ARY009 respectively; Proteome 
Profiler™ R&D Systems, Abingdon, UK). The assays 
were performed in accordance with the manufacturer’s 
instructions. Briefly, cell lysates were diluted, layered on 
nitrocellulose membranes and incubated overnight at 4° C 
on a rocking platform. The membranes were washed to 
remove unbound proteins and incubated with a cocktail of 
biotinylated detection antibodies for 2 h. The subsequent 
application of Streptavidin-HRP and chemiluminescent 
detection reagents (ECL) allowed displaying a signal 
for each point of capture, corresponding to the amount 
of bound protein. Multiple time exposures were used to 
verify the linearity of the samples analyzed. The spots 
obtained were scanned and quantified by densitometric 
analysis using ImageJ software (NIH) and results were 
expressed as arbitrary units (a.u.).
The average signal of the pair of duplicate spots, 
representing each protein, was calculated after subtraction 
of background values (pixel density) from negative control 
spots and normalization to average values from internal 
positive control spots.
Cell cycle analysis
Cell cycle distribution changes were evaluated using 
the Acridine Orange (AO) technique  described previously 
[43]. The percentage of cells in the G0, G1, S, and G2M 
were determined by measuring simultaneously the DNA 
and RNA total cellular content. The percentage of apoptotic 
cells was measured based on the decreased stainability of 
apoptotic elements in DNA green fluorescence (sub-G1 
peak on DNA-frequency histograms) coupled with a higher 
RNA red fluorescence (which is common to chromatin 
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Table 1: List of proteins and corresponding phosphorylation site detected in the study
Phospho-proteins
MAPKs family p38α (T180/Y182)
ERK1/2 (T202/Y204, T185/Y187)
CREB (S133)
JNK pan  (T183/Y185, T221/Y223)
MSK1/2 (S376/S360)
RSK1/2/3 (S380/S386/S377)
RSK1/2 (S221/S227)
 c-JUN (S63)
PI3K/Akt/mTOR pathway AKT (S473)
AKT (T308)
mTOR (S2448)
p70 S6 Kinase (T389)
p70 S6 Kinase (T421/S424)
p70 S6 Kinase (T229)
 PLCγ-1 (Y783)
STATs family STAT2 (Y689)
STAT3 (Y705)
STAT5a (Y694)
STAT5b (Y699)
STAT5a7b (Y694/Y699)
STAT6 (Y641)
STAT1 (Y701)
 STAT4 (Y693)
p53 p53 (S392)
p53 (S46)
 p53 (S15)
Src family Src (Y419)
Lyn (Y397)
Lck (Y394)
Fyn (Y420)
Yes (Y426)
Fgr (Y412)
 Hck (Y411)
FAK subfamily FAK (Y397)
 Pyk2 (Y402)
Multi functional kinase GSK-3α/β (s21/S9)
Cell cycle checkpoint Chk-2 (T68)
Cell cycle inhibitors p27 (T198)
 p27 (T157)
Cell growth,adhesion and migration β-Catenin 
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Molecular chaperones HSP27 (S78/S82)
Homeostasis sensors      AMPKα1 (T174)
AMPKα2 (T172)
eNOS (S1177)
Signal transduction adaptor Paxillin (Y118)
Table 2: List of apoptosis related proteins detected in the study
Apoptosis related proteins
Bcl-2 family Bad
Bax
Bcl-2
 Bcl-x
Death receptors TRAIL R1/DR4
TRAIL R2/DR5
FADD
Fas/TNFRSF6
 TNF R1/TNFRSF1A
Caspase Pro-Caspase-3
 Cleaved-Caspase-3
Apoptosis inhibitors cIAP-1
cIAP-2
XIAP
Livin
 Survivin
Apoptosis activators Cytochrome c
 SMAC/Diablo
Molecular chaperones HO-1/HMOX1/HSP32
HO-2/HMOX2
HSP27
HSP60
HSP70
HTRA2/Omi
 Clusterin
ROS scavenging Catalase
 PON2
Cell cycle inhibitors p21/CIP1/CDNK1A
 p27/Kip1
Cellular checkpoint Claspin
phospho-Rad17 (S635)
Transcription factor HIF-1a
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condensation); cell debris were excluded from the analysis 
on the basis of their forward light scatter properties. Cell-
cycle distribution was analyzed using the ModFit LT 
software (Verity Software House, Topsham, ME).
Statistical analysis
Statistical analysis was performed using Microsoft 
Excel software. Student’s t test was used to analyze 
significant differences. Results were considered to be 
statistically significant if P < 0.05. Results were expressed 
as mean ± SE between groups.
ACKNOWLEDGMENTS
We thank RomAIL (Associazione Italiana contro le 
Leucemie, linfomi e mieloma) for providing laboratory 
space, David Calef for editing the manuscript and 
somersault1824.com for graphical elements in Figure 4.
CONFLICTS OF INTEREST
The authors have no conflicts of interest to declare.
GRANT SUPPORT
This work was supported by Sapienza University 
(C26A158NJR) and MIUR (PRIN 2008 NYJZXB_005) 
grants, by Fondazione Frisiani-Santini and Fondazione 
Internazionale D’Amato ONLUS.
REFERENCES
1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused 
transcript of abl and bcr genes in chronic myelogenous 
leukaemia. Nature. 1985; 315:550–554. 
2. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, 
Baltimore D. The chronic myelogenous leukemia-specific 
P210 protein is the product of the bcr/abl hybrid gene. 
Science. 1986; 233:212–214.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, 
Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-
Jones S, Sawyers CL. Efficacy and Safety of a Specific 
Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic 
Myeloid Leukemia. N Engl J Med. 2001; 344:1031–1037.
 4. Breccia M, Alimena G, Baccarani M, Bocchia M, Di 
Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, 
Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, 
et al. Current management of CML patients: Summary of 
the Italian Consensus Meeting held in Rome, April 11-12, 
2013. Crit Rev Oncol Hematol. 2014; 90:181–189.
 5. Yilmaz M, Jabbour E. Tyrosine Kinase Inhibitors Early in 
the Disease Course: Lessons From Chronic Myelogenous 
Leukemia. Semin Oncol. 2015; 42:876–886.
 6. Steegmann JL, Baccarani M, Breccia M, Casado LF, García-
Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le 
Coutre P, Mayer J, Milojkovic D, Porkka K, et al. European 
LeukemiaNet recommendations for the management and 
avoidance of adverse events of treatment in chronic myeloid 
leukaemia. Leukemia. 2016; 30:1648–1671.
 7. Hughes TP, Ross DM. Targeted therapies: Remembrance 
of things past - discontinuation of second-generation TKI 
therapy for CML. Nat Rev Clin Oncol. 2017; 14:201–202.
 8. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, 
Hughes TP, Baccarani M, Deininger MW, Cervantes F, 
Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, et al. 
Long-Term Outcomes of Imatinib Treatment for Chronic 
Myeloid Leukemia. N Engl J Med. 2017; 376:917–927.
 9. Hochhaus A, La Rosée P. Imatinib therapy in chronic 
myelogenous leukemia: strategies to avoid and overcome 
resistance. Leukemia. 2004; 18:1321–1331.
10. Roychowdhury S, Talpaz M. Managing resistance in 
chronic myeloid leukemia. Blood Rev. 2011; 25:279–290.
11. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, 
Rostagno R, Scapozza L. Molecular mechanisms of 
resistance to imatinib in Philadelphia-chromosome-positive 
leukaemias. Lancet Oncol. 2003; 4:75–85.
12. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, 
Richmond L, Holyoake TL. Primitive, quiescent, 
Philadelphia-positive stem cells from patients with chronic 
myeloid leukemia are insensitive to STI571 in vitro. Blood. 
2002; 99:319–325.
13. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW. 
Pushing the limits of targeted therapy in chronic myeloid 
leukaemia. Nat Rev Cancer. 2012; 12:513–526.
14. Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R. 
Emerging therapeutic strategies for targeting chronic myeloid 
leukemia stem cells. Stem Cells Int. 2013; 2013:724360.
15. Savona M, Talpaz M. Getting to the stem of chronic 
myeloid leukaemia. Nat Rev Cancer. 2008; 8:341–350.
16. Holyoake TL, Vetrie D. The chronic myeloid leukemia 
stem cell: stemming the tide of persistence. Blood. 2017; 
129:1595–1606.
17. Sinclair A, Latif AL, Holyoake TL. Targeting survival 
pathways in chronic myeloid leukaemia stem cells. Br J 
Pharmacol. 2013; 169:1693–1707.
18. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, 
Dent P, Grant S. Pharmacologic mitogen-activated protein/
extracellular signal-regulated kinase kinase/mitogen-
activated protein kinase inhibitors interact synergistically 
with STI571 to induce apoptosis in Bcr/Abl-expressing 
human leukemia cells. Cancer Res. 2002; 62:188–199.
19. Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, 
Kalaitzidis D, Lane SW, Armstrong SA. Genetic and 
Pharmacologic Inhibition of β-Catenin Targets Imatinib-
Resistant Leukemia Stem Cells in CML. Cell Stem Cell. 
2012; 10:412–424.
Oncotarget21768www.oncotarget.com
20. Xu X, Zhang X, Liu Y, Yang L, Huang S, Lu L, Wang S, 
Guo Q, Zhao L. BM microenvironmental protection of 
CML cells from imatinib through Stat5/NF-κB signaling 
and reversal by Wogonin. Oncotarget. 2016; 7:24436–54. 
https://doi.org/10.18632/oncotarget.8332.
21. Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, 
Buest S, Bruennert D, Huenerlituerkoglu AN, 
Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, 
et al. The hematopoietic stem cell in chronic phase CML is 
characterized by a transcriptional profile resembling normal 
myeloid progenitor cells and reflecting loss of quiescence. 
Leukemia. 2009; 23:892–899.
22. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, 
Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, 
Rohr UP, Kobbe G, et al. Molecular signature of CD34+ 
hematopoietic stem and progenitor cells of patients with 
CML in chronic phase. Leukemia. 2007; 21:494–504.
23. Villuendas R, Steegmann JL, Pollán M, Tracey L, 
Granda A, Fernández-Ruiz E, Casado LF, Martínez J, 
Martínez P, Lombardía L, Villalón L, Odriozola J, Piris MA. 
Identification of genes involved in imatinib resistance in 
CML: a gene-expression profiling approach. Leukemia. 
2006; 20:1047–1054.
24. Visvader J, Lindeman G. Cancer Stem Cells: Current 
Status and Evolving Complexities. Cell Stem Cell. 2012; 
10:717–728.
25. Seke Etet PF, Vecchio L, Nwabo Kamdje AH. Signaling 
pathways in chronic myeloid leukemia and leukemic stem 
cell maintenance: Key role of stromal microenvironment. 
Cell Signal. 2012; 24:1883–1888.
26. Bourgeais J, Ishac N, Medrzycki M, Brachet-Botineau M, 
Desbourdes L, Gouilleux-Gruart V, Pecnard E, Rouleux-
Bonnin F, Gyan E, Domenech J, Mazurier F, Moriggl R, 
Bunting KD, et al. Oncogenic STAT5 signaling promotes 
oxidative stress in chronic myeloid leukemia cells by 
repressing antioxidant defenses. Oncotarget. 2017; 
8:41876–41889. https://doi.org/10.18632/oncotarget.11480.
27. Warsch W, Grundschober E, Berger A, Gille L, Cerny-
Reiterer S, Tigan AS, Hoelbl-Kovacic A, Valent P, 
Moriggl R, Sexl V. STAT5 triggers BCR-ABL1 mutation by 
mediating ROS production in chronic myeloid leukaemia. 
Oncotarget. 2012; 3:1669–87. https://doi.org/10.18632/
oncotarget.806.
28. Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, 
Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, 
Rabascio C, Rossi L, Martin-Padura I, et al. Molecular and 
functional analysis of the stem cell compartment of chronic 
myelogenous leukemia reveals the presence of a CD34- 
cell population with intrinsic resistance to imatinib. Blood. 
2009; 114:5191–5200.
29. Lemoli RM, Bertolini F, Petrucci MT, Gregorj C, 
Ricciardi MR, Fogli M, Curti A, Rabascio C, Pandolfi 
S, Ferrari S, Foá R, Baccarani M, Tafuri A, et al. 
Functional and kinetic characterization of granulocyte 
colony-stimulating factor-primed CD34- human stem cells. 
Br J Haematol. 2003; 123:720–729.
30. Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, 
Vala M, Nelson WG, Jones RJ, Yegnasubramanian S. 
Genome-wide comparison of the transcriptomes of highly 
enriched normal and chronic myeloid leukemia stem and 
progenitor cell populations. Oncotarget. 2013; 4:715–28. 
https://doi.org/10.18632/oncotarget.990.
31. Xiong L, Zhang J, Yuan B, Dong X, Jiang X, Wang Y. 
Global proteome quantification for discovering imatinib-
induced perturbation of multiple biological pathways in 
K562 human chronic myeloid leukemia cells. J Proteome 
Res. 2010; 9:6007–6015.
32. Quintàs-Cardama A, Qiu YH, Post SM, Zhang Y, 
Creighton CJ, Cortes J, Kornblau SM. Reverse phase 
protein array profiling reveals distinct proteomic signatures 
associated with chronic myeloid leukemia progression and 
with chronic phase in the CD34-positive compartment. 
Cancer. 2012; 118:5283–5292.
33. Zhang J, Jin Z, Du Q, Li R, Yao F, Huang B, Xu N, Xu L, 
Luo X, Liu X. Analysis of altered proteins related to blast 
crisis in chronic myeloid leukemia by proteomic study. Int 
J Lab Hematol. 2012; 34:267–273.
34. Peng X, Gong F, Xie G, Zhao Y, Tang M, Yu L, Tong A. A 
proteomic investigation into adriamycin chemo-resistance 
of human leukemia K562 cells. Mol Cell Biochem. 2011; 
351:233–241.
35. Alaiya AA, Aljurf M, Shinwari Z, Almohareb F, 
Malhan H, Alzahrani H, Owaidah T, Fox J, Alsharif F, 
Mohamed SY, Rasheed W, Aldawsari G, Hanbali A, et al. 
Protein signatures as potential surrogate biomarkers for 
stratification and prediction of treatment response in chronic 
myeloid leukemia patients. Int J Oncol. 2016; 49:913–933.
36. Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, 
Leng X, Munsell M, Bar-Eli M, Arlinghaus RB, Chandra J. 
BCR-ABL1 mediates up-regulation of Fyn in chronic 
myelogenous leukemia. Blood. 2008; 111:2904–2908.
37. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, 
Arlinghaus R, Talpaz M. BCR-ABL independence and LYN 
kinase overexpression in chronic myelogenous leukemia 
cells selected for resistance to STI571. Blood. 2003; 
101:690–698.
38. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq 
S, Lippert E, Roche S, Mahon FX, Pasquet JM. Quantitative 
phosphoproteomics revealed interplay between Syk and Lyn 
in the resistance to nilotinib in chronic myeloid leukemia 
cells. Blood. 2011; 118:2211–2221.
39. Lemoli RM, Tafuri A, Fortuna A, Petrucci MT, 
Ricciardi MR, Catani L, Rondelli D, Fogli M, Leopardi G, 
Ariola C, Tura S. Cycling status of CD34+ cells mobilized 
into peripheral blood of healthy donors by recombinant 
human granulocyte colony-stimulating factor. Blood. 1997; 
89:1189–1196.
Oncotarget21769www.oncotarget.com
40. Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, 
McQueen T, Cortes J, Kantarjian HM, Champlin RE, 
Konopleva M, Andreeff M. Synergistic effects of p53 
activation via MDM2 inhibition in combination with 
inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating 
and quiescent chronic myeloid leukemia blast crisis cells. 
Oncotarget. 2015; 6:30487–30499. https://doi.org/10.18632/
oncotarget.5890.
41. Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn 
K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, 
Pellicano F, Pierce A, Copland M, et al. Dual targeting of 
p53 and c-MYC selectively eliminates leukaemic stem 
cells. Nature. 2016; 534:341–346.
42. Salati S, Salvestrini V, Carretta C, Genovese E, 
Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, 
Barbieri G, Curti A, Castagnetti F, Gugliotta G, et al. 
Deregulated expression of miR-29a-3p, miR-494-3p and 
miR-660-5p affects sensitivity to tyrosine kinase inhibitors 
in CML leukemic stem cells. Oncotarget. 2017; 8:49451–
49469. https://doi.org/10.18632/oncotarget.17706.
43. Tafuri A, Meyers J, Lee BJ, Andreeff M. DNA and RNA 
flow cytometric study in multiple myeloma. Clinical 
correlations. Cancer. 1991; 67:449–454.
